

Meeting of the Psychopharmacologic Drugs Advisory Committee

February 6, 2008

Crowne Plaza Silver Spring
Silver Spring, Maryland

Meeting Roster

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (PDAC) (Voting)

Rochelle Caplan, M.D.

Professor, Semel Institute for Neuroscience
And Human Behavior, UCLA
Los Angeles, CA

Gail W. Griffith, M.L.S. (Consumer Representative)

Writer and Activist
Washington, DC

Barbara G. Wells, Pharm.D.

Professor and Dean of School of Pharmacy
University of Mississippi
University, MS

TEMPORARY VOTING MEMBERS

Dean A. Follmann, Ph.D.

Assistant Director for Biostatistics, NIAID
Chief Biostatistics Research Branch National
Institute of Allergy and Infectious Diseases,
National Institutes of Health
Bethesda, MD

Barbara Geller, M.D.

Professor, Department of Psychiatry
Washington University in St. Louis
St. Louis, MO

Margy Lawrence (Patient Representative)

Potomac, MD

Andrew Leon, Ph.D.

Professor of Biostatistics in Psychiatry
Department of Psychiatry, Weill Medical
College of Cornell University
New York, NY

J. John Mann, M.D.

New York State Psychiatric Institute
Department of Neuroscience
New York, NY

Matthew V. Rudorfer, M.D. (Acting Chair)

Adult Treatment and Preventive Interventions
Research Branch, Division of Services and
Intervention Research
National Institute of Mental Health
Bethesda, MD

David Shaffer, F.R.C.P. (Lond), F.R.C. Psych.
(Lond)

Irving Philips Professor of Child Psychiatry
Professor of Psychiatry and Pediatrics Director,
Division of Child and Adolescent Psychiatry
Columbia University/NYS Psychiatric Institute
New York, NY

Meeting of the Psychopharmacologic Drugs Advisory Committee

February 6, 2008

Crowne Plaza Silver Spring

Silver Spring, Maryland

Meeting Roster

Andrew Winokur, M.D., Ph.D.

Department of Psychiatry

University of Connecticut Health Center

Farmington, CT

INDUSTRY REPRESENTATIVE

(Non-Voting)

William Z. Potter, M.D., Ph.D.

Vice President, Translational Neuroscience

Merck & Co., Inc.

North Wales, PA

Meeting of the Psychopharmacologic Drugs Advisory Committee

February 6, 2008

Crowne Plaza Silver Spring
Silver Spring, Maryland

Meeting Roster

FDA PARTICIPANTS (Non-Voting)

Robert Temple, M.D.

Director, Office of Drug Evaluation I
Office of New Drugs, CDER, FDA

Thomas P. Laughren, M.D.

Director, Division of Psychiatry Products
Office of Drug Evaluation I
Office of New Drugs, CDER, FDA

CDR Mitchell Mathis, M.D.

Deputy Director, Division of Psychiatry Products
Office of Drug Evaluation I
Office of New Drugs, CDER, FDA

Gwen Zornberg, M.D.

Medical Team Leader, Division of Psychiatry Products
Office of Drug Evaluation I
Office of New Drugs, CDER, FDA